Clinical Trial Update: BIOLUMA: Biomarkers for Nivolumab and Ipilimumab and Evaluation of the Combination in Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating biomarkers for nivolumab and ipilimumab and their combination in lung cancer.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Carcinoma
• Small Cell Lung Carcinoma

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Lung Cancer Group Cologne | Conditions: Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell Lung | Phase 2 | Status: COMPLETED